Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Covington
Johnson and Johnson
Cerilliant
Harvard Business School
Deloitte
McKinsey
Citi
Federal Trade Commission

Generated: May 26, 2018

DrugPatentWatch Database Preview

INTAL Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Drug patent expirations by year for INTAL
Medical Subject Heading (MeSH) Categories for INTAL
Synonyms for INTAL
1,3-bis-(2-carboxychromon-5-yloxy)propan-2-ol
1,3-Bis(2-carboxychromon-5-yloxy)-2-hydroxypropane
1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol
1,3-Di(2-carboxy-4-oxochromen-5-yloxy)propan-2-ol
15826-37-6 (Parent)
16110-51-3
4H-1-Benzopyran-2-carboxylic acid, {5,5'-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-,}
4H-1-Benzopyran-2-carboxylic acid, 5, {5'-[(2-hydroxytrimethylene)dioxy]bis(4-oxo-,}
4H-1-Benzopyran-2-carboxylic acid, 5,5'-((2-hydroxy-1,3-propanediyl)bis(oxy))bis(4-oxo-
4H-1-Benzopyran-2-carboxylic acid, 5,5'-((2-hydroxytrimethylene)dioxy)bis(4-oxo- (8CI)
4H-1-Benzopyran-2-carboxylic acid, 5,5'-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-
4H-1-Benzopyran-2-carboxylicacid, 5,5'-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-
5-(3-((2-Carboxy-4-oxo-4H-chromen-5-yl)oxy)-2-hydroxypropoxy)-4-oxo-4H-chromene-2-carboxylic acid
5-[3-(2-carboxy-4-oxo-4H-5-chromenyloxy)-2-hydroxypropoxy]-4-oxo-4H-2-chromenecarboxylic acid
5-[3-(2-carboxy-4-oxo-chromen-5-yl)oxy-2-hydroxy-propoxy]-4-oxo-chromene-2-carboxylic acid
5-[3-(2-carboxy-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid
5-{3-[(2-carboxy-4-oxo-4H-chromen-5-yl)oxy]-2-hydroxypropoxy}-4-oxo-4H-chromene-2-carboxylic acid
5,5'-((2-Hydroxypropane-1,3-diyl)bis(oxy))bis(4-oxo-4H-chromene-2-carboxylic acid)
5,5'-(2-Hydroxytrimethylenedioxy)bis(4-oxochromene-2-carboxylic acid)
5,5'-[(2-hydroxypropane-1,3-diyl)bis(oxy)]bis(4-oxo-4H-chromene-2-carboxylic acid)
Aarane
Aararre
AC-12785
AC1L1EON
Acide cromoglicique
Acido cromoglicico
Acidum cromoglicicum
AJ-26694
AK-60415
AKOS015961001
Altoderm
ANW-71958
API0000493
AX8053784
BDBM50440033
BIDD:GT0397
BPBio1_000775
BSPBio_000703
BSPBio_002093
C06928
CHEBI:59773
CHEMBL428880
Chromoglycate
Chromolyn
Cromo asma aerosol
Cromo-Comod (TN)
Cromoglicate
Cromoglicic acid
Cromoglicic acid (INN)
Cromoglycate
Cromoglycic acid
cromolyn
cromolyn disodium
Cromolyn disodium salt
Cromolyn sodium (topical, atopic dermatitis)
Cromolyn sodium (topical, atopic dermatitis), Manhattan Pharmaceuticals
CTK0H5278
D07753
D0B9GH
D0G7IY
DB01003
Dinatrium cromoglicicum
DivK1c_000857
DTXSID4022860
FPL 670
Frenasma
FT-0082559
FT-0601561
GTPL7608
IDI1_000857
IMZMKUWMOSJXDT-UHFFFAOYSA-N
J-009783
KB-244061
KBio1_000857
KBio2_001332
KBio2_003900
KBio2_006468
KBio3_001313
KBioGR_000884
KBioSS_001332
Lomudal
Lomudas
Lomusol
Nalcrom
Nasmil
NCGC00021142-01
NCGC00021142-02
NCGC00159523-01
NCI60_000229
Nebulasma
NINDS_000857
NSC109500
O542
Oprea1_077850
Opticrom
Prestwick0_000812
Prestwick1_000812
Prestwick2_000812
Prestwick3_000812
Rynacrom
SBI-0051323.P003
SCHEMBL3865
Sodium Chromoglycate
Sodium chromoglycate, sanofi-aventis
sodium cromoglicate
SPBio_001033
SPBio_002624
Spectrum_000852
Spectrum2_001137
Spectrum3_000367
Spectrum4_000302
Spectrum5_000791
TC-030058
UNII-Y0TK0FS77W
Y0TK0FS77W
ZINC1530788

US Patents and Regulatory Information for INTAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms Llc INTAL cromolyn sodium AEROSOL, METERED;INHALATION 018887-001 Dec 5, 1985 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us INTAL cromolyn sodium CAPSULE;INHALATION 016990-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
King Pharms Llc INTAL cromolyn sodium SOLUTION;INHALATION 018596-001 May 28, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for INTAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us INTAL cromolyn sodium CAPSULE;INHALATION 016990-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
King Pharms Llc INTAL cromolyn sodium AEROSOL, METERED;INHALATION 018887-001 Dec 5, 1985 ➤ Sign Up ➤ Sign Up
King Pharms Llc INTAL cromolyn sodium AEROSOL, METERED;INHALATION 018887-001 Dec 5, 1985 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us INTAL cromolyn sodium CAPSULE;INHALATION 016990-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Daiichi Sankyo
Cipla
Medtronic
Julphar
Johnson and Johnson
Federal Trade Commission
Teva
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.